eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2022
vol. 17
 
Share:
Share:
abstract:
Letter to the Editor

Inflammatory bowel disease induced by bimekizumab

Dominika Wietrzykowska-Grishanovich
1
,
Maciej Pleskacz
1
,
Radosław Kempiński
2

  1. Department of Gastroenterology and Hepatology, University Hospital, Wroclaw, Poland
  2. Department of Gastroenterology and Hepatology, University Hospital, Wroclaw Medical University, Wroclaw, Poland
Gastroenterology Rev 2022; 17 (2): 175–176
Online publish date: 2022/05/19
View full text Get citation
 
PlumX metrics:
Inflammatory bowel disease (IBD) is a chronic condition of the gastrointestinal tract, with a complex aetiopathogenesis in which genetic, immunological, and environmental factors are being discussed. The development of knowledge about molecular processes and the aetiology of diseases are made possible the implementation of modern therapies with biological drugs, which are a heterogeneous group of substances working by modulating the body’s immune response. Currently, biological medications are used in an increasing number of indications.
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.